Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > November 1, 2022
Daily News
November 1, 2022
- Daiichi Sankyo Nets Double-Digit Rise in H1 Sales as Major Products Fare Well
November 1, 2022
- Shionogi’s H1 Operating Profit Sinks 33.8% on COVID-Linked R&D Expenses
November 1, 2022
- Otsuka Logs 13.6% Growth in 9-Month Pharma Sales on 4 Global Products
November 1, 2022
- Sumitomo Braced for Red Ink to Continue in FY2023 on Latuda LOE
November 1, 2022
- Moderna’s BA.4/5 COVID Booster Nabs Special Approval in Japan
November 1, 2022
- Sumitomo Posts 7.3 Billion Yen Net Loss in H1 on Kynmobi Write-Down
November 1, 2022
- Ono’s April-September Sales Zoom 24.5% on Bullish Opdivo and Forxiga
November 1, 2022
- Label Expansion for TS-1, Enhertu and More in Line for November Approval
November 1, 2022
- Takeda, Shionogi to Wind Up Copromotion for 2 ADHD Products
November 1, 2022
- Average Price Gap for 2023 Revision Looks to Be a Bit Lower than 7.6%: Wholesalers
November 1, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…